Strategic Spain Expansion Synthon is expanding operations in Spain with additional facility space near its Sant Boi site as of June 2026, signaling potential for increased supply capacity, regional partnerships, and local market penetration opportunities for generic medicines and complex generics.

Complex Generics Capabilities Recent moves to expand oligonucleotide development capacity in Blansko and Synthon's focus on complex generics position the company to capture demand for advanced, affordable therapies, creating sales opportunities with biopharma and specialty channels seeking complex product manufacturing.

Strategic Licensing The exclusive licensing and supply agreement with Zydus Group for Ozanimod Capsules in the United States indicates Synthon’s capability to partner for niche, high-value products, suggesting avenues to pursue similar collaborations for other complex or MAb-adjacent generics.

Global Access Focus With regulatory approvals in over 90 countries and a mission to improve access through high-quality generics, there are sales opportunities in markets prioritizing affordability and expanded access programs, especially in regions balancing pricing and affordability.

Sustainability as Differentiator EcoVadis Silver Medal and recognized responsible practices provide a differentiator for tendering and collaboration opportunities with health systems and NGOs that prioritize sustainability credentials alongside cost, enabling targeted bids and partnerships.